NEW DELHI – Accelerating its expansion into the preventive healthcare and diagnostics market, Redcliffe Labs has announced the appointment of Mr. Satish Chandra Paliwal as Director – National Sales.
The appointment, effective April 1, 2026, follows Mr. Paliwal’s successful tenure as Chief Operating Officer (COO) at Krsnaa Diagnostics. He brings over 25 years of leadership experience across the Indian healthcare, pharmaceutical, and diagnostics sectors.
Strategic Sales and Market Expansion
In his new role, Mr. Paliwal will spearhead Redcliffe Labs’ national offline sales operations, focusing on:
-
Market Penetration: Driving deeper reach into Tier-2 and Tier-3 cities as diagnostics shift from episodic testing to continuous health management.
-
Partner Ecosystem: Strengthening the network of collection centers and hospital partnerships to scale the company’s national footprint.
-
Customer Engagement: Enhancing the “preventive-led” diagnostic model to improve long-term patient retention and service accessibility.
A Veteran of Indian Healthcare
Mr. Paliwal’s career spans two and a half decades with some of the most prominent names in the industry:
-
Diagnostics Expertise: Prior leadership roles at Metropolis Healthcare, Sterling Accuris, and Krsnaa Diagnostics.
-
Pharma & Wellness: Significant experience at Abbott India, Cipla, Ranbaxy, and The Himalaya Drug Company.
Leadership Perspectives
“Satish brings a sharp understanding of market dynamics and a proven ability to build high-impact partnerships, which will be instrumental in accelerating our growth,” stated Aditya Kandoi, Founder & CEO of Redcliffe Labs.
Mr. Paliwal noted that Redcliffe is well-positioned for its next phase of growth, which will be defined by “sharper execution and a more scalable sales ecosystem.”
Industry Context
The move comes at a time when the Indian diagnostic industry is undergoing a digital and physical transformation. By bringing in a veteran with extensive “execution-driven” experience, Redcliffe Labs signals its intent to dominate the domestic market through high-quality, accessible testing services for the 2026-27 fiscal year.
